Parkinson's disease historical perspective: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
Parkinson disease was first documented and recognized by a British physician, [[James Parkinson]] in 1817 who named it paralysis agitans. The first underlying [[pathology]] of Parkinson disease was described by a German [[pathologist]] Frederick Lewy in 1912. He described that there are [[cytoplasmic]] [[inclusions]] in some [[brain]] areas of [[Parkinson's disease|PD]] patients. in 1967 the drug “[[L-dopa]]” was introduced to the market as a treatment of Parkinson ’s disease. | |||
==Historical Perspective== | ==Historical Perspective== | ||
=== Discovery === | === Discovery === | ||
* Parkinson | * Parkinson disease was first documented and recognized by a British physician, [[James Parkinson]] in 1817 who named it paralysis agitans. | ||
* The current name of the disease (Parkinson disease) is from [[Jean-Martin Charcot]]. | * The current name of the disease (Parkinson disease) is from [[Jean-Martin Charcot]]. | ||
* The first underlying [[pathology]] of Parkinson disease was described by a German [[pathologist]] Frederick Lewy in 1912. He described that there are [[cytoplasmic]] [[inclusions]] in some [[brain]] areas of [[Parkinson's disease|PD]] patients. | * The first underlying [[pathology]] of Parkinson disease was described by a German [[pathologist]] Frederick Lewy in 1912. He described that there are [[cytoplasmic]] [[inclusions]] in some [[brain]] areas of [[Parkinson's disease|PD]] patients. | ||
| Line 16: | Line 16: | ||
* Finally in the 1950s [[dopamine]] depletion was known to be the underlying [[Causes|cause]] of the disease.<ref name="pmid17017502">{{cite journal |vauthors=Hornykiewicz O |title=The discovery of dopamine deficiency in the parkinsonian brain |journal=J. Neural Transm. Suppl. |volume= |issue=70 |pages=9–15 |date=2006 |pmid=17017502 |doi= |url=}}</ref> | * Finally in the 1950s [[dopamine]] depletion was known to be the underlying [[Causes|cause]] of the disease.<ref name="pmid17017502">{{cite journal |vauthors=Hornykiewicz O |title=The discovery of dopamine deficiency in the parkinsonian brain |journal=J. Neural Transm. Suppl. |volume= |issue=70 |pages=9–15 |date=2006 |pmid=17017502 |doi= |url=}}</ref> | ||
* Later, in 1967 the drug “[[L-dopa]]” was introduced to the market as a treatment of Parkinson ’s disease.<ref name="pmid10410773">{{cite journal |vauthors=Manyam BV, Sánchez-Ramos JR |title=Traditional and complementary therapies in Parkinson's disease |journal=Adv Neurol |volume=80 |issue= |pages=565–74 |date=1999 |pmid=10410773 |doi= |url=}}</ref><ref name="pmid11983801">{{cite journal |vauthors=Parkinson J |title=An essay on the shaking palsy. 1817 |journal=J Neuropsychiatry Clin Neurosci |volume=14 |issue=2 |pages=223–36; discussion 222 |date=2002 |pmid=11983801 |doi=10.1176/jnp.14.2.223 |url=}}</ref><ref name="pmid12373520">{{cite journal |vauthors=Hornykiewicz O |title=L-DOPA: from a biologically inactive amino acid to a successful therapeutic agent |journal=Amino Acids |volume=23 |issue=1-3 |pages=65–70 |date=2002 |pmid=12373520 |doi=10.1007/s00726-001-0111-9 |url=}}<nowiki><ref name="pmid5637779"></nowiki>{{cite journal |vauthors=Cotzias GC |title=L-Dopa for Parkinsonism |journal=N. Engl. J. Med. |volume=278 |issue=11 |pages=630 |date=March 1968 |pmid=5637779 |doi= |url=}}</ref> | * Later, in 1967 the drug “[[L-dopa]]” was introduced to the market as a treatment of Parkinson ’s disease.<ref name="pmid10410773">{{cite journal |vauthors=Manyam BV, Sánchez-Ramos JR |title=Traditional and complementary therapies in Parkinson's disease |journal=Adv Neurol |volume=80 |issue= |pages=565–74 |date=1999 |pmid=10410773 |doi= |url=}}</ref><ref name="pmid11983801">{{cite journal |vauthors=Parkinson J |title=An essay on the shaking palsy. 1817 |journal=J Neuropsychiatry Clin Neurosci |volume=14 |issue=2 |pages=223–36; discussion 222 |date=2002 |pmid=11983801 |doi=10.1176/jnp.14.2.223 |url=}}</ref><ref name="pmid12373520">{{cite journal |vauthors=Hornykiewicz O |title=L-DOPA: from a biologically inactive amino acid to a successful therapeutic agent |journal=Amino Acids |volume=23 |issue=1-3 |pages=65–70 |date=2002 |pmid=12373520 |doi=10.1007/s00726-001-0111-9 |url=}}<nowiki><ref name="pmid5637779"></nowiki>{{cite journal |vauthors=Cotzias GC |title=L-Dopa for Parkinsonism |journal=N. Engl. J. Med. |volume=278 |issue=11 |pages=630 |date=March 1968 |pmid=5637779 |doi= |url=}}</ref> | ||
== References == | == References == | ||
Revision as of 17:12, 20 February 2019
|
Parkinson's disease Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Parkinson's disease historical perspective On the Web |
|
American Roentgen Ray Society Images of Parkinson's disease historical perspective |
|
Risk calculators and risk factors for Parkinson's disease historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.
Overview
Parkinson disease was first documented and recognized by a British physician, James Parkinson in 1817 who named it paralysis agitans. The first underlying pathology of Parkinson disease was described by a German pathologist Frederick Lewy in 1912. He described that there are cytoplasmic inclusions in some brain areas of PD patients. in 1967 the drug “L-dopa” was introduced to the market as a treatment of Parkinson ’s disease.
Historical Perspective
Discovery
- Parkinson disease was first documented and recognized by a British physician, James Parkinson in 1817 who named it paralysis agitans.
- The current name of the disease (Parkinson disease) is from Jean-Martin Charcot.
- The first underlying pathology of Parkinson disease was described by a German pathologist Frederick Lewy in 1912. He described that there are cytoplasmic inclusions in some brain areas of PD patients.
- Later on in 1919 Tretiakoff showed that in this patients’ substantia nigra there are evidences of neuronal loss.
- Finally in the 1950s dopamine depletion was known to be the underlying cause of the disease.[1]
- Later, in 1967 the drug “L-dopa” was introduced to the market as a treatment of Parkinson ’s disease.[2][3][4]
References
- ↑ Hornykiewicz O (2006). "The discovery of dopamine deficiency in the parkinsonian brain". J. Neural Transm. Suppl. (70): 9–15. PMID 17017502.
- ↑ Manyam BV, Sánchez-Ramos JR (1999). "Traditional and complementary therapies in Parkinson's disease". Adv Neurol. 80: 565–74. PMID 10410773.
- ↑ Parkinson J (2002). "An essay on the shaking palsy. 1817". J Neuropsychiatry Clin Neurosci. 14 (2): 223–36, discussion 222. doi:10.1176/jnp.14.2.223. PMID 11983801.
- ↑ Hornykiewicz O (2002). "L-DOPA: from a biologically inactive amino acid to a successful therapeutic agent". Amino Acids. 23 (1–3): 65–70. doi:10.1007/s00726-001-0111-9. PMID 12373520.<ref name="pmid5637779">Cotzias GC (March 1968). "L-Dopa for Parkinsonism". N. Engl. J. Med. 278 (11): 630. PMID 5637779.